INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION 12-Month Results

• Type: Article in International Scientific Journal
• Date: 2010

Authors

Silva, RM (Author) Other; Ruiz Moreno, JM (Author) Other; Rosa, P (Author) Other; Ângela Carneiro (Author) FMUP; Nascimento, J (Author) Other; Rito, LF (Author) Other; Cachulo, ML (Author) Other; Carvalheira, F (Author) Other; Murta, JN (Author) Other

Journal

Title: Retina

Vol. 30

Pages: 407-412

ISSN: 0275-004X

Publisher: Wolters Kluwer Health

Indexing

ISI Web of Knowledge - 71 Citations

Scopus - 80 Citations

Other information

Authenticus ID: P-003-906

DOI: 10.1097/iae.0b013e3181c9691e

Abstract (EN): Purpose: The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia. Methods: This was a prospective, multicenter, consecutive, nonrandomized, interventional case series. The study included 34 eyes of 32 patients with choroidal neovascularization secondary to pathologic myopia; 13 eyes had previous photodynamic therapy, and 21 eyes had no previous treatment. The patients were followed for >= 12 months. Best-corrected visual acuity, optical coherence tomography, and the presence of metamorphopsia were assessed monthly. Results: Mean visual acuity improved 8 letters from baseline to 12-month follow-up, and the difference was statistically significant (P < 0.001): 100% of the eyes lost <3 lines on the Early Treatment Diabetic Retinopathy Study chart, 24% of the eyes improved >= 3 lines, 44% improved >= 2 lines, 65% improved >= 1 line, and 79% improved >= 0 lines. Central retinal thickness decreased significantly from baseline to the 12-month follow-up (P < 0.01). A mean of 3.6 treatments were performed during the 12-month follow-up, and no systemic or ocular side effects were registered during that time. Conclusion: One-year results of intravitreal ranibizumab for myopic choroidal neovascularization are very promising. Additional prospective studies are necessary to better determine long-term efficacy and safety. RETINA 30: 407-412, 2010

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6